Should I buy Sotera Health (SHC) stock or is it too late?

Sotera Health · Health Care · price $19

See the full Sotera Health (SHC) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Citigroup — 64% of its targets hit on this sector (125 calls tested). It aims for $25 (+28 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).

The 2 reliable analysts $22.50+16 %

The 3 other firms $22+13 %

How to read it: the 2 reliable firms are not filtered by optimism — 2 aim above the price, 0 below, hence their $22.50 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Sotera Health

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
RBC Capital	30 %	+3.9 %	10	$17 -13%
Barclays	29 %	-12.9 %	17	$22 +13%
Keybanc	0 %	-23.6 %	5	$23 +18%

In short — Should you invest in Sotera Health? Is it too late, still worth it? Analysts are overwhelmingly positive (80% buy, median target $22, i.e. +13%), and the most reliable on SHC targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

80% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
Median price target $22, i.e. +13% from the current price ($19).
The most reliable firm on SHC, Goldman Sachs (33% hit rate, 3 scored calls), targets $20 (call made on June 5, 2026, maturing on June 5, 2027) (+3%) in its most recent call.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 5 ratings, 1 is neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on SHC

Median target $22 (+13%) · 5 ratings · Buy consensus

Strong Buy00%

Buy480%

Hold120%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Sotera Health now?

We won't decide for you. The facts: 80% of analysts rate it a buy, median target $22 (+13%), and Goldman Sachs (most reliable on SHC, 33%) targets $20. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Sotera Health?

Not according to analysts: the median target ($22) is still +13% above the current price ($19) (most reliable on SHC: Goldman Sachs, 33%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Sotera Health still worth investing in?

It depends on the gap between the price ($19) and its estimated value: analysts target $22 on median (+13%), with 80% buys (most reliable on SHC: Goldman Sachs, 33%). Cross-check with their real reliability on SHC and the cautions above. Information, not advice.

What's the main risk in buying SHC?

The consensus is not unanimous: of 5 ratings, 1 is neutral.

→ Go deeper: the full Sotera Health profile (consensus, analyst reliability, price target, performance).